Huhn, S
Weinhold, N
Nickel, J
Pritsch, M
Hielscher, T
Hummel, M
Bertsch, U
Huegle-Doerr, B
Vogel, M
Angermund, R
Hänel, M
Salwender, H J
Weisel, K
Dürig, J
Görner, M
Kirchner, H
Peter, N
Graeven, U
Lordick, F
Hoffmann, M
Reimer, P
Blau, I W
Jauch, A
Dembowsky, K
Möhler, T
Wuchter, P
Goldschmidt, H
Article History
First Online: 15 May 2017
Competing interests
: SH, NW, JN, MP, TH, MHu, UB, BH-D, MHä, JD, MG, HK, UG, MHo, PR, AJ, NP and KD declare no conflict of interest. MV and RA are employees of Janssen and hold stock in Johnson & Johnson; HJS—Celgene: honoraria, travel grants and Amgen: honoraria; KW—Honoraria and Advisory Board von Amgen, BMS, Celgene, Janssen, Novartis, Takeda; FL—advisory role: BioNTech, Bristol-Myers-Squibb, Eli Lilly, GANYMED Pharmaceuticals, Merck Sharp & Dohme, Roche Pharma AG. Lecture honoraria: Amgen, Astra Zeneca, Eli Lilly, Merck Sharp & Dohme, Roche Pharma AG, Servier. Research grant: Boehringer Ingelheim, Fresenius Biotech. Travel grants: Amgen, Bayer, Merck Sharp & Dohme, Roche Pharma AG, Taiho Pharmaceutical; IWB—scientific grants Jabssen-Cilag and Celgene. TM is an employee of inVentiv Health; PW—Honoraria and membership on Advisory Boards of Sanofi-Aventis. Membership on Advisory Boards and Travel Grants from Hexal AG; HG—research support (institutions): Celgene, Janssen, Chugai, Novartis, BMS; Advisory Boards (institutions): Janssen, Celgene, Novartis, Amgen Takeda, BMS; Honoraria: Celgene, Janssen, Novartis, Chugai, BMS.